Home > Services
Brixadi, a new treatment option for opioid use disorder, offers significant benefits by providing extended-release buprenorphine in a convenient and consistent manner. Its unique formulation allows for either weekly or monthly administration, ensuring steady medication levels, which can enhance adherence and reduce the risk of relapse. This extended-release mechanism also minimizes the daily decision-making burden on patients, supporting long-term recovery and stability. Additionally, Brixadi’s extended coverage can help manage withdrawal symptoms and cravings more effectively, contributing to improved overall outcomes in opioid use disorder treatment.
